| (Values in U.S. Thousands) | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 | Dec, 2014 |
| Sales | -9,999,000 | 5,820 | 5,200 | 4,400 | 9,890 |
| Sales Growth | -171,904.09% | +11.92% | +18.18% | -55.51% | +31.17% |
| Net Income | -9,999,000 | -8,150 | -16,280 | -30 | 7,020 |
| Net Income Growth | -122,587.13% | +49.94% | -54,168.48% | -100.43% | +4.00% |
Pozen Inc (POZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.